Litcius/Paper detail

Mendelian susceptibility to mycobacterial disease—Challenges in hematopoietic stem cell transplantation

Shivani Patel, Ramya Uppuluri, Venkateswaran Vellaichamy Swaminathan, Nikila Ravichandran, Kesavan Melarcode Ramanan, Revathi Raj

2020Pediatric Blood & Cancer18 citationsDOI

Abstract

We present our experience in the hematopoietic stem cell transplantation (HSCT) in two children diagnosed with Mendelian susceptibility to mycobacterial diseases. The first child underwent a haploidentical HSCT with posttransplant cyclophosphamide using a reduced intensity conditioning following which he had primary graft failure. He was subsequently found to have interferon-γ1 receptor deficiency. He had immune reconstitution and is on antitubercular therapy. The second child diagnosed with IL12RB1 gene mutation underwent matched sibling donor HSCT with myeloablative conditioning following pretransplant immunosuppression with fludarabine and dexamethasone. He is 13 months post-HSCT with complete and remains disease free.

Topics & Concepts

MedicineHematopoietic stem cell transplantationFludarabineCyclophosphamideSavior siblingTransplantationDiseaseImmunosuppressionImmunologyOncologyInternal medicineChemotherapyMycobacterium research and diagnosisImmunodeficiency and Autoimmune DisordersImmune Cell Function and Interaction
Mendelian susceptibility to mycobacterial disease—Challenges in hematopoietic stem cell transplantation | Litcius